Potential therapeutic biomarkers in plasma cell myeloma: A flow cytometry study

Cytometry Part B - Clinical Cytometry

Volumn 84, Issue 4, 2013, Pages 222-228

  Zheng, Wenli ^a,b   Liu, Dingshen ^a   Fan, Xiangshan ^a   Powers, Linda ^a   Goswami, Maitrayee ^a   Hu, Ying ^a   Lin, Pei ^a   Medeiros, L Jeffrey ^a   Wang, Sa A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

CD105; CD184; CD30; CD44; CD49d; CD70; plasma cell myeloma

Indexed keywords

ALPHA4 INTEGRIN; BIOLOGICAL MARKER; CD19 ANTIGEN; CD20 ANTIGEN; CD28 ANTIGEN; CD30 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CD70 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; ENDOGLIN; HERMES ANTIGEN; STEM CELL FACTOR RECEPTOR; SYNDECAN 1;

ADULT; AGED; ARTICLE; BONE MARROW; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BIOLOGICAL MARKERS; BONE MARROW CELLS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MULTIPLE MYELOMA;

EID: 84879330419     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.21083     Document Type: Article

References (29)

1. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC,. Multiple myeloma. Lancet 2009; 374: 324-339.
2. Podar K, Anderson KC,. Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies. Curr Cancer Drug Targets 2011; 11: 1005-1024.
3. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A,. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812-1821.
4. McEarchern JA, Oflazoglu E, Francisco L, McDonagh CF, Gordon KA, Stone I, Klussman K, Turcott E, van Rooijen N, Carter P, et al. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood 2007; 109: 1185-1192.
5. McEarchern JA, Smith LM, McDonagh CF, Klussman K, Gordon KA, Morris-Tilden CA, Duniho S, Ryan M, Boursalian TE, Carter PJ, et al. Preclinical characterization of SGN-70, a humanized antibody directed against CD70. Clin Cancer Res 2008; 14: 7763-7772.
6. Oflazoglu E, Stone IJ, Gordon K, Wood CG, Repasky EA, Grewal IS, Law CL, Gerber HP,. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res 2008; 14: 6171-6180.
7. Peled A, Wald O, Burger J,. Development of novel CXCR4-based therapeutics. Exp Opin Investig Drugs 2012; 21: 341-353.
8. Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM, Kulkarni S, Abboud CN, Cashen AF, Stockerl-Goldstein KE, and others. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 2012; 119: 3917-3924.
9. Agathangelidis A, Darzentas N, Hadzidimitriou A, Brochet X, Murray F, Yan XJ, Davis Z, van Gastel-Mol EJ, Tresoldi C, Chu CC, et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: A molecular classification with implications for targeted therapies. Blood 2012; 119: 4467-4475.
10. Feng Y, Wen J, Mike P, Choi DS, Eshoa C, Shi ZZ, Zu Y, Chang CC,. Bone marrow stromal cells from myeloma patients support the growth of myeloma stem cells. Stem Cells Dev 2010; 19: 1289-1296.
11. Kim HY, Hwang JY, Kim SW, Lee HJ, Yun HJ, Kim S, Jo DY,. The CXCR4 Antagonist AMD3100 Has Dual Effects on Survival and Proliferation of Myeloma Cells In Vitro. Cancer Res Treat 2010; 42: 225-234.
12. Ghosh SC, Neslihan Alpay S, Klostergaard J,. CD44: A validated target for improved delivery of cancer therapeutics. Exp Opin Ther Targets 2012; 16: 635-650.
13. Liebisch P, Eppinger S, Schopflin C, Stehle G, Munzert G, Dohner H, Schmid M,. CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q. Haematologica 2005; 90: 489-493.
14. Katz BZ,. Adhesion molecules-The lifelines of multiple myeloma cells. Semin Cancer Biol 2010; 20: 186-195.
15. Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, Hartung HP, Havrdova E, Hillert J, Hohlfeld R, et al. Natalizumab treatment for multiple sclerosis: Updated recommendations for patient selection and monitoring. Lancet Neurol 2011; 10: 745-758.
16. Podar K, Zimmerhackl A, Fulciniti M, Tonon G, Hainz U, Tai YT, Vallet S, Halama N, Jager D, Olson DL, et al. The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications. Br J Haematol 2011; 155: 438-448.
17. Nassiri F, Cusimano MD, Scheithauer BW, Rotondo F, Fazio A, Yousef GM, Syro LV, Kovacs K, Lloyd RV,. Endoglin (CD105): A review of its role in angiogenesis and tumor diagnosis, progression and therapy. Anticancer Res 2011; 31: 2283-2290.
18. Seon BK, Haba A, Matsuno F, Takahashi N, Tsujie M, She X, Harada N, Uneda S, Tsujie T, Toi H, and others. Endoglin-targeted cancer therapy. Curr Drug Deliv 2011; 8: 135-143.
19. Liu D, Lin P, Hu Y, Zhou Y, Tang G, Powers L, Medeiros LJ, Jorgensen JL, Wang SA,. Immunophenotypic heterogeneity of normal plasma cells: Comparison with minimal residual plasma cell myeloma. J Clin Pathol 2012; 65: 823-829.
20. Zheng W, Medeiros LJ, Hu Y, Powers L, Cortes JE, Ravandi-Kashani F, Kantarjian HH, Wang SA,. CD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk 2013 [Epub ahead of print].
21. Kraj M, Kopec-Szlezak J, Poglod R, Kruk B,. Flow cytometric immunophenotypic characteristics of 36 cases of plasma cell leukemia. Leuk Res 2011; 35: 169-176.
22. Ohwada C, Nakaseko C, Koizumi M, Takeuchi M, Ozawa S, Naito M, Tanaka H, Oda K, Cho R, Nishimura M, et al. CD44 and hyaluronan engagement promotes dexamethasone resistance in human myeloma cells. Eur J Haematol 2008; 80: 245-250.
23. Schmidt-Hieber M, Perez-Andres M, Paiva B, Flores-Montero J, Perez JJ, Gutierrez NC, Vidriales MB, Matarraz S, San Miguel JF, Orfao A,. CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features. Haematologica 2011; 96: 328-332.
24. Horie R, Watanabe T,. CD30: Expression and function in health and disease. Semin Immunol 1998; 10: 457-470.
25. Beschorner R, Horny HP, Petruch UR, Kaiserling E,. Frequent expression of haemopoietic and non-haemopoietic antigens by reactive plasma cells: An immunohistochemical study using formalin-fixed, paraffin-embedded tissue. Histol Histopathol 1999; 14: 805-812.
26. Tsirakis G, Pappa CA, Spanoudakis M, Chochlakis D, Alegakis A, Psarakis FE, Stratinaki M, Stathopoulos EN, Alexandrakis MG,. Clinical significance of sCD105 in angiogenesis and disease activity in multiple myeloma. Eur J Intern Med 2012; 23: 368-373.
27. Lutz RJ, Whiteman KR,. Antibody-maytansinoid conjugates for the treatment of myeloma. MAbs 2009; 1: 548-551.
28. Richardson PG, Lonial S, Jakubowiak AJ, Harousseau JL, Anderson KC,. Monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol 2011; 154: 745-754.
29. Benson DM Jr, Byrd JC,. CS1-directed monoclonal antibody therapy for multiple myeloma. J Clin Oncol 2012; 30: 2013-2015.